BOSTON– Kernal Biologics, Inc., a venture-backed therapeutics company developing in vivo cell therapies that program human cells directly inside the body, announced its relocation to Lilly Gateway Labs (LGL) in Boston.
Lilly Gateway Labs, located within Eli Lilly and Company’s Seaport Innovation Center, is an accelerator designed to support early-stage biotechs by providing state-of-the-art lab facilities, tailored scientific engagement, and direct access to Lilly scientists, researchers, and executives. Companies accepted into the program benefit from shared resources, operational support, and Lilly’s global expertise, while retaining full strategic independence.
“We are honored to join this vibrant innovation hub and advance our therapeutic programs in such a collaborative environment,” said Yusuf Erkul, M.D., MBA, co-founder and CEO of Kernal Bio. “The Gateway Labs model offers tailored support for companies at our stage, allowing us to stay focused on our scientific mission while benefiting from Lilly’s deep expertise.”
Kernal Bio recently introduced its proprietary large language model for mRNA design, kernaLM™, at the 2nd Annual Computational RNA Design & Delivery Summit. The model has demonstrated significant performance improvements over existing state-of-the-art platforms. Following this achievement, the company was accepted into NVIDIA’s Inception program, gaining access to advanced computational infrastructure and resources.
“Support from NVIDIA and Lilly will help us scale our AI-driven solutions and accelerate our pipeline of transformative therapies,” said Burak Yilmaz, M.S., co-founder and president of Kernal Bio.
